|
|
|||
|
| |||
|
| |||
|
| |||
|
|
|||
|
Seyed-Moayed Alavian, Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah Research Center for Gastroenterology and Liver Disease, Tehran 1998136194, Iran Author contribution: Alavian SM contributed all to this paper. Correspondence to: Seyed-Moayed Alavian, Professor, Internal Medicine, Gastroenterology and Hepatology, Baqiyatallah Research Center for Gastroenterology and Liver Disease, Vanaq Square, Mola Sadra St., PO Box 14155-3651, Tehran 1998136194, Iran. alavian@thc.ir Telephone: +98-21-88945186 Fax: +98-21-88945188 Received: May 12, 2008 Revised: July 15, 2008 Accepted: July 22, 2008 Published online: February 14, 2009
Abstract Hepatitis C virus (HCV) infection is highly prevalent among patients on hemodialysis (HD). The prevalence of HCV infection in HD patients varies markedly from country to country. Some factors are especially related to these high prevalence rates, such as blood transfusions and length of dialysis time. Nosocomial routes of transmission including the use of contaminated equipment and patient-to-patient exposure is considered more important. Several prophylactic measures have been suggested to avoid infection by HCV in the HD environment.
© 2009 The WJG Press and Baishideng. All rights reserved.
Key words: Dialysis; Epidemiology; Hepatitis C virus; Incidence; Isolation; Nosocomial transmission; Prevalence; Prevention; Universal precaution
Alavian SM. A shield against a monster: Hepatitis C in hemodialysis patients. World J Gastroenterol 2009; 15(6): 641-646 Available from: URL: http://www.wjgnet.com/1007-9327/15/641.asp DOI: http://dx.doi.org/10.3748/wjg.15.641
INTRODUCTION Hepatitis C virus (HCV) infection is considered a major public health problem worldwide. Patients with chronic renal failure who are on hemodialysis (HD) have a high prevalence of HCV. They are among the highest risk groups for the acquisition of HCV infection[1-3]. Prevalence of HCV infection has decreased in this group in recent years[4], but still remains a significant public health concern. HCV-infected patients on HD have significant liver disease and a decreased life expectancy[5,6]. The relative risk for death in HCV-infected patients on HD compared with non-infected patients is greater than 1.4[6-8]. In addition, HCV infection leads to decreased graft and patient survival in renal transplant recipients[9,10]. On the other hand, due to the increased prevalence of non-communicable diseases such as diabetes mellitus and hypertension, and their complications, chronic renal failure has become a more serious health issue throughout the world[11]. Therefore, the clinical importance of HCV has been increasingly recognized in the dialysis community.
PREVALENCE AND INCIDENCE HCV prevalence in HD varies geographically, both within and between countries[12]. The reported anti-HCV seropositivity since 1999 ranges from low (1.9%) in the Slovenian 2001 Annual Report[13] to high (80%) in Senegal[14]. HCV seroprevalence in the HD population was 59% in Bosnia and Herzegovina[15] , 6.8% in Belgium[16], 16.3% in France[2], 6.1% in Germany[17], 10%-29% in Greece[18-20], 22.5%-32.1% in Italy[21,22], 75% in Moldavia[23], 3.4% in the Netherlands[24], 1.9% in Slovenia[13], 11% in Sweden[25], 7%-23.3% in the USA[26-30], 4% in the UK[31] 20.5% in Libya[32], 71% in Kuwait[31] 80% in Senegal[14], 23.7% in Sudan[33], 19%-41.7% in Tunisia[34,35], 8.4%-43.2% in Brazil[36-39], 6.7% in Mexico[40], 59.3% in Peru[41], 3.5% in Puerto Rico[42] and 13.2% in Iran[43]. Some investigators have suggested a decline in HCV prevalence among HD patients in recent years, mostly attributable to strict adherence to universal precautions with[16,44-49] or without[50,51] observing isolation measures. This decrease is more significant in the USA and European countries[4,16,47,52]. Studies that have prospectively followed HD patients for their HCV serostatus have yielded annual incidence rates of de novo HCV infection of 0.4% in France[53], 0.5% in Tunisia[54], 0.5% in the Netherlands[24], 0.83% in Italy[55], 1.38%[56] and 2.1%[57] in the USA, 0.33%[58], 2.59%[59], 3.1% in Japan[60], 3.7%[61] 5.5% in Brazil[62], and 6.2% in Greece[20]. This variation in different countries and different centers underlines the importance of infection control. New infection was evidently more frequent at centers that had higher anti-HCV prevalence and failure in infection control measures. In some countries, both prevalence and incidence remain very high, indicating major ongoing nosocomial transmission, probably due to the limited resources available to treat a rapidly growing HD population[63,64].
RISK FACTORS FOR HCV TRANSMISSION The high prevalence of HCV seropositivity among HD patients was initially attributed to blood transfusions for the treatment of uremic anemia in this population, which were often necessary[41,65-68]. Historically, the number of blood transfusions received was consistently reported in the literature to be associated with an increased prevalence of HCV-positive dialysis patients[31]. However, several recent reports have failed to recognize blood transfusion as an independent risk factor in HCV spread among HD subjects[2,20,23,24,30,33,62,69-74]. Indeed, from the late 1980s onward, the prescription of erythropoietin reduced the need for blood transfusion in HD patients. Furthermore, the introduction of sensitive tests for screening blood donors has markedly reduced the risk of HCV transmission through blood product transfusion. These two reasons may explain recent findings on the lack of association between blood transfusion and HCV infection. Nonetheless, considering the fact that new HCV infections do still occur in patients without a history of transfusion, the duration of HD is increasingly being considered as a risk factor for HCV infection[75,76]. Almost all recent surveys on the subject have congruently suggested that the length of time on HD is a risk factor for HCV seropositivity[17,20,23,29,30,33,36,39,43,60,69-71,77-80]. Nosocomial patient-to-patient transmission of HCV infection among HD patients has been suggested by several investigators who performed phylogenetic analysis of HCV viral isolates[24,25,53,54,81-84]. Lack of strict adherence to universal precautions by staff and sharing of articles such as multidose drugs might be the main mode of nosocomial HCV spread among HD patients[54,82,84-86]. Although some studies found that nosocomial spread of HCV declined when HCV-infected patients were treated in dedicated HD units[44-49,87,88], other investigators could control nosocomial spread of HCV among HD patients by the strict application of hygienic precautions, without isolation of HCV-infected subjects or machine segregation[12,50,89]. Indeed, the observed efficacy of isolation might simply be due to the prevented sharing of articles between patients and might reflect a better implementation of other hygienic precautions. The spread of HCV infection in HD units is mainly due to nosocomial transmission between patients[53,88,90-94]. The importance of this route of transmission is demonstrated by the high HCV prevalence in some HD units and by the lower infection rate in patients on peritoneal dialysis compared with those on HD. A high prevalence of patients with HCV infection in HD facilities has been considered a risk factor for transmission of the infection. However, there is no consensus on the necessity for infection control isolation of HCV-positive patients for at least two reasons: firstly, the infectivity of HCV is lower than that of the hepatitis B virus; and secondly, the criteria for patients to be isolated remain to be defined. On the contrary, some HD patients are infected with HCV but do not have antibodies. Detection of viral RNA by reverse-transcription polymerase chain reaction (RT-PCR) is the only method to confirm HCV infection, however, this technique is not available at all centers.
PREVENTIVE STRATEGIES Several prophylactic measures have been suggested to avoid infection by HCV in the HD environment, and range from isolating patients with HCV infection[44,47,48,88,95], to adopting a series of biosafety measures specific for HD, such as preparing medications in a separate area, cleaning and disinfecting dialysis station surfaces, washing hands and changing gloves between patient contacts, and items dedicated for use only with a single patient[12,39,50,96]. Strict adherence to universal infection control precautions seems to be enough to control the spread of disease in HD units[12,50,89,97-99]. Some reports have recommended the adoption of infection control isolation measures at centers with a high HCV prevalence[47,87,100,101] or if the staff/patient ratio at the center is lower than 28/100[102]. At centers with a high prevalence of HCV infection and in developing countries, universal precautions may not always be possible to implement. Thus isolation measures for HCV-positive patients should be implemented[47]. The CDC recommends that special precautions be observed in dialysis units including the wearing and changing of gloves and water-proof gowns between patients; systematic decontamination of the equipment, circuits, and surfaces after each patient treatment; no sharing of instruments (e.g. tourniquets) or medications (e.g. multiuse vials of heparin) among patients; and the assignment of patients to specific HD units[97]. Clearly, it is necessary to attempt, one step at a time, to minimize intradialytic or intracenter HCV transmission.
CONCLUSION In summary, despite the marked decrease in anti-HCV prevalence in HD patients in many countries, the disappearance of HCV from HD units should not be expected for decades. Universal infection control precautions are the keystone in the prevention of nosocomial HCV transmission in HD units; however, isolation measures, including health care monitoring of infected patients and providing care in a dedicated section of the unit, improve prevention results. Those HD units with a high HCV prevalence or in which there is no fulltime infection control personnel dedicated to the infected patients during HD sessions may have a greater risk of seroconversion. Therefore, isolation in special units or dialyzing patients in specific sessions must be considered[44]. As HCV-infected HD patients serve as a reservoir of infection for other patients, HD staff, and the transplant team[28,103,104] at HD centers must be aware of new HCV infections in order to review their practices and increase vigilance. Public health authorities should be aware about the prevalence and incidence of HCV infection in HD patients in different cities in their respective countries, so that changes can be proposed and the risks of infection among patients can be assessed. Implementation of surveillance systems and continuing education of the unit’s personnel on recommended infection control measures in HD units are necessary. The treatment of most HCV-infected patients with interferon alpha can significantly contribute to decreasing HCV infection in this group in the future[105]. Successful control of infection requires further studies to assess the effectiveness of different preventive policies.
REFERENCES 1 Barril G. Hepatitis C virus-induced liver disease in dialysis patients. Nephrol Dial Transplant 2000; 15 Suppl 8: 42-45 PubMed DOI 2 Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: a multicenter study. J Med Virol 2000; 61: 44-51 PubMed DOI 3 Alavian SM, Hosseini-Moghaddam SM, Rahnavardi M. Hepatitis C among hemodialysis patients: a review on epidemiologic, diagnostic, and therapeutic features. Hep Mon 2007; 7: 153-162 4 Espinosa M, Martn-Malo A, Ojeda R, Santamara R, Soriano S, Aguera M, Aljama P. Marked reduction in the prevalence of hepatitis C virus infection in hemodialysis patients: causes and consequences. Am J Kidney Dis 2004; 43: 685-689 PubMed DOI 5 Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-263 PubMed
6
7 Pereira BJ, Natov SN, Bouthot BA, Murthy BV, Ruthazer R, Schmid CH, Levey AS. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int 1998; 53: 1374-1381 PubMed DOI 8 Hanafusa T, Ichikawa Y, Kishikawa H, Kyo M, Fukunishi T, Kokado Y, Okuyama A, Shinji Y, Nagano S. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 471-476 PubMed DOI 9 Gentil MA, Rocha JL, Rodríguez-Algarra G, Pereira P, López R, Bernal G, Muñoz J, Naranjo M, Mateos J. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999; 14: 2455-2460 PubMed DOI
10
11 Aghighi M, Heidary Rouchi A, Zamyadi M, Mahdavi-Mazdeh M, Norouzi S, Rajolani H, Ahrabi S, Zamani M. Dialysis in Iran. IJKD 2008; 2: 11-15 12 Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998; 53: 1022-1025 PubMed DOI 13 Buturović-Ponikvar J. Renal replacement therapy in Slovenia: annual report 2001. Nephrol Dial Transplant 2003; 18 Suppl 5: v53-v55 PubMed DOI 14 Diouf ML, Diouf B, Niang A, Ka EH, Pouye A, Seck A, Raphenon G, Moreira-Diop T. [Prevalence of hepatitis B and C viruses in a chronic hemodialysis center in Dakar] Dakar Med 2000; 45: 1-4 PubMed 15 Ahmetagić S, Muminhodzić K, Cickusić E, Stojić V, Petrović J, Tihić N. Hepatitis C infection in risk groups. Bosn J Basic Med Sci 2006; 6: 13-17 PubMed 16 Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, Barril G, Scheuermann E, Sonkodi S, Goubau P. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant 2004; 19: 904-909 PubMed DOI 17 Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Fölsch UR, Schmidt WE. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002; 51: 429-433 PubMed DOI 18 Rigopoulou EI, Stefanidis I, Liaskos C, Zervou EK, Rizos C, Mina P, Zachou K, Syrganis C, Patsidis E, Kyriakopoulos G, Sdrakas L, Tsianas N, Dalekos GN. HCV-RNA qualitative assay based on transcription mediated amplification improves the detection of hepatitis C virus infection in patients on hemodialysis: results from five hemodialysis units in central Greece. J Clin Virol 2005; 34: 81-85 PubMed DOI 19 Garinis G, Spanakis N, Theodorou V, Gorgoulis V, Manolis E, Karameris A, Valis D. Comparison of the enzyme-linked immunosorbant assay III, recombinant immunoblot third generation assay, and polymerase chain reaction method in the detection of hepatitis C virus infection in haemodialysis patients. J Clin Lab Anal 1999; 13: 122-125 PubMed DOI 20 Sypsa V, Psichogiou M, Katsoulidou A, Skoutelis G, Moutafis S, Hadjiconstantinou V, Kakavas J, Kalapothaki V, Boletis J, Hatzakis A. Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am J Kidney Dis 2005; 45: 334-343 PubMed DOI 21 Lombardi M, Cerrai T, Geatti S, Negroni S, Pertusini L, Pegoraro M, Di Lullo G. Results of a national epidemiological investigation of HCV infection in dialysis patients. EDTNA ERCA J 1999; 25: 38-42 PubMed 22 Petrosillo N, Gilli P, Serraino D, Dentico P, Mele A, Ragni P, Puro V, Casalino C, Ippolito G. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis 2001; 37: 1004-1010 PubMed DOI 23 Covic A, Iancu L, Apetrei C, Scripcaru D, Volovat C, Mititiuc I, Covic M. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999; 14: 40-45 PubMed DOI 24 Schneeberger PM, Keur I, van Loon AM, Mortier D, de Coul KO, van Haperen AV, Sanna R, van Der Heijden TG, van Den Hoven H, van Hamersvelt HW, Quint W, van Doorn LJ. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis 2000; 182: 1291-1299 PubMed DOI 25 Almroth G, Ekermo B, Månsson AS, Svensson G, Widell A. Detection and prevention of hepatitis C in dialysis patients and renal transplant recipients. A long-term follow up (1989-January 1997). J Intern Med 2002; 251: 119-128 PubMed DOI 26 Kelley VA, Everett-Kitchens J, Brannon LE, Connor K, Martinez EJ, Pearson TC, Nolte FS. Lack of seronegative hepatitis C virus infections in patients with chronic renal failure. Transplantation 2002; 74: 1473-1475 PubMed DOI 27 Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis 2005; 46: 290-300 PubMed DOI 28 Saab S, Martin P, Brezina M, Gitnick G, Yee HF Jr. Serum alanine aminotransferase in hepatitis c screening of patients on hemodialysis. Am J Kidney Dis 2001; 37: 308-315 PubMed DOI 29 Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, Kopple JD, Greenland S. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007; 18: 1584-1593 PubMed DOI 30 Sivapalasingam S, Malak SF, Sullivan JF, Lorch J, Sepkowitz KA. High prevalence of hepatitis C infection among patients receiving hemodialysis at an urban dialysis center. Infect Control Hosp Epidemiol 2002; 23: 319-324 PubMed DOI 31 Wreghitt TG. Blood-borne virus infections in dialysis units--a review. Rev Med Virol 1999; 9: 101-109 PubMed DOI 32 Daw MA, Elkaber MA, Drah AM, Werfalli MM, Mihat AA, Siala IM. Prevalence of hepatitis C virus antibodies among different populations of relative and attributable risk. Saudi Med J 2002; 23: 1356-1360 PubMed 33 El-Amin HH, Osman EM, Mekki MO, Abderlraheem MB, Ismail MO, Yousif MEA, Abass A, Elhaj HS, Ammar HK. Hepatitis C virus infection in hemodialysis patients in Sudan:Two centers report. Saudi J Kidney Dis Transplant 2007; 18: 101-106 34 Bouzgarrou N, Fodha I, Othman SB, Achour A, Grattard F, Trabelsi A, Pozzetto B. Evaluation of a total core antigen assay for the diagnosis of hepatitis C virus infection in hemodialysis patients. J Med Virol 2005; 77: 502-508 PubMed DOI 35 Ayed K, Gorgi Y, Ben Abdallah T, Aouadi H, Jendoubi-Ayed S, Sfar I, Makni H. Hepatitis C virus infection in hemodialysis patients from Tunisia: national survey by serologic and molecular methods. Transplant Proc 2003; 35: 2573-2575 PubMed DOI 36 Albuquerque AC, Coêlho MR, Lopes EP, Lemos MF, Moreira RC. Prevalence and risk factors of hepatitis C virus infection in hemodialysis patients from one center in Recife, Brazil. Mem Inst Oswaldo Cruz 2005; 100: 467-470 PubMed 37 Lopes EP, Gouveia EC, Albuquerque AC, Sette LH, Mello LA, Moreira RC, Coelho MR. Determination of the cut-off value of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia. J Clin Virol 2006; 35: 298-302 PubMed DOI 38 Mello Lde A, de Melo-Junior MR, de Albuquerque AC, Coelho MR. [Hepatitis C serum prevalence in hemodialyzed patients] Rev Soc Bras Med Trop 2007; 40: 290-294 PubMed DOI 39 Carneiro MA, Martins RM, Teles SA, Silva SA, Lopes CL, Cardoso DD, Vanderborght BO, Yoshida CF. Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: a survey by polymerase chain reaction and serological methods. Mem Inst Oswaldo Cruz 2001; 96: 765-769 PubMed 40 Méndez-Sánchez N, Motola-Kuba D, Chavez-Tapia NC, Bahena J, Correa-Rotter R, Uribe M. Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico. J Clin Microbiol 2004; 42: 4321-4322 PubMed DOI 41 Sanchez JL, Sjogren MH, Callahan JD, Watts DM, Lucas C, Abdel-Hamid M, Constantine NT, Hyams KC, Hinostroza S, Figueroa-Barrios R, Cuthie JC. Hepatitis C in Peru: risk factors for infection, potential iatrogenic transmission, and genotype distribution. Am J Trop Med Hyg 2000; 63: 242-248 PubMed 42 López-Navedo PJ, Lebrón-Rivera R, González-Trápaga J, Weber-Acevedo J, Lefevre-Ramos E, Flores-de Hostos E, Jaume-Anselmi F, Ramírez-Rivera J. Prevalence of hepatitis C virus infection at three hemodialysis units in the western region of Puerto Rico. Bol Asoc Med P R 1999; 91: 100-102 PubMed 43 Alavian SM, Einollahi B, Hajarizadeh B, Bakhtiari S, Nafar M, Ahrabi S. Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology (Carlton) 2003; 8: 256-260 PubMed DOI 44 Yang CS, Chang HH, Chou CC, Peng SJ. Isolation effectively prevents the transmission of hepatitis C virus in the hemodialysis unit. J Formos Med Assoc 2003; 102: 79-85 PubMed 45 Gallego E, López A, Pérez J, Llamas F, Lorenzo I, López E, Illescas ML, Andrés E, Olivas E, Gómez-Roldan C. Effect of isolation measures on the incidence and prevalence of hepatitis C virus infection in hemodialysis. Nephron Clin Pract 2006; 104: c1-c6 PubMed DOI 46 Carneiro MA, Teles SA, Dias MA, Ferreira RC, Naghettine AV, Silva SA, Lampe E, Yoshida CF, Martins RM. Decline of hepatitis C infection in hemodialysis patients in Central Brazil: a ten years of surveillance. Mem Inst Oswaldo Cruz 2005; 100: 345-349 PubMed 47 Barril G, Traver JA. Decrease in the hepatitis C virus (HCV) prevalence in hemodialysis patients in Spain: effect of time, initiating HCV prevalence studies and adoption of isolation measures. Antiviral Res 2003; 60: 129-134 PubMed DOI 48 Shamshirsaz AA, Kamgar M, Bekheirnia MR, Ayazi F, Hashemi SR, Bouzari N, Habibzadeh MR, Pourzahedgilani N, Broumand V, Shamshirsaz AH, Moradi M, Borghei M, Haghighi NN, Broumand B. The role of hemodialysis machines dedication in reducing Hepatitis C transmission in the dialysis setting in Iran: a multicenter prospective interventional study. BMC Nephrol 2004; 5: 13 PubMed DOI 49 Saxena AK, Panhotra BR, Sundaram DS, Naguib M, Venkateshappa CK, Uzzaman W, Mulhim KA. Impact of dedicated space, dialysis equipment, and nursing staff on the transmission of hepatitis C virus in a hemodialysis unit of the middle east. Am J Infect Control 2003; 31: 26-33 PubMed DOI 50 Valtuille R, Moretto H, Lef L, Rendo P, Fernández JL. Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow-up. Clin Nephrol 2002; 57: 371-375 PubMed 51 Aucella F, Vigilante M, Valente GL, Stallone C. Systematic monitor disinfection is effective in limiting HCV spread in hemodialysis. Blood Purif 2000; 18: 110-114 PubMed DOI 52 dos Santos JP, Loureiro A, Cendoroglo Neto M, Pereira BJ. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant 1996; 11: 2017-2022 PubMed 53 Izopet J, Sandres-Sauné K, Kamar N, Salama G, Dubois M, Pasquier C, Rostaing L. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol 2005; 77: 70-76 PubMed DOI 54 Hmaied F, Ben Mamou M, Saune-Sandres K, Rostaing L, Slim A, Arrouji Z, Ben Redjeb S, Izopet J. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J Med Virol 2006; 78: 185-191 PubMed DOI 55 Lombardi M, Cerrai T, Geatti S, Negroni S, Pertusini L, Pegoraro M, Di Lullo G. Results of a national epidemiological investigation on HCV infection among dialysis patients. (Survey by the Italian Branch of EDTNA/ERCA). J Nephrol 1999; 12: 322-327 PubMed 56 Fabrizi F, de Vecchi AF, Como G, Lunghi G, Martin P. De novo HCV infection among dialysis patients: a prospective study by HCV core antigen ELISA assay. Aliment Pharmacol Ther 2005; 21: 861-869 PubMed DOI 57 Fabrizi F, Martin P, Dixit V, Brezina M, Russell J, Conrad A, Schmid P, Gerosa S, Gitnick G. Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients. Am J Nephrol 1999; 19: 383-388 PubMed DOI 58 Kumagai J, Komiya Y, Tanaka J, Katayama K, Tatsukawa Y, Yorioka N, Miyakawa Y, Yoshizawa H. Hepatitis C virus infection in 2,744 hemodialysis patients followed regularly at nine centers in Hiroshima during November 1999 through February 2003. J Med Virol 2005; 76: 498-502 PubMed DOI 59 Furusyo N, Hayashi J, Kakuda K, Ariyama I, Kanamoto-Tanaka Y, Shimizu C, Etoh Y, Shigematsu M, Kashiwagi S. Acute hepatitis C among Japanese hemodialysis patients: a prospective 9-year study. Am J Gastroenterol 2001; 96: 1592-1600 PubMed DOI 60 Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, Greenwood RN, Akiba T, Young EW. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004; 65: 2335-2342 PubMed DOI 61 Moreira R, Pinho JR, Fares J, Oba IT, Cardoso MR, Saraceni CP, Granato C. Prospective study of hepatitis C virus infection in hemodialysis patients by monthly analysis of HCV RNA and antibodies. Can J Microbiol 2003; 49: 503-507 PubMed DOI 62 Santos MA, Souto FJ. Infection by the hepatitis C virus in chronic renal failure patients undergoing hemodialysis in Mato Grosso state, central Brazil: a cohort study. BMC Public Health 2007; 7: 32 PubMed DOI 63 Vladutiu DS, Cosa A, Neamtu A, State D, Braila M, Gherman M, Patiu IM, Dulau-Florea I. Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a blank map? J Viral Hepat 2000; 7: 313-319 PubMed DOI 64 Rutkowski B. Changing pattern of end-stage renal disease in central and eastern Europe. Nephrol Dial Transplant 2000; 15: 156-160 PubMed DOI 65 Zeldis JB, Depner TA, Kuramoto IK, Gish RG, Holland PV. The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med 1990; 112: 958-960 PubMed 66 Santana GO, Cotrim HP, Mota E, Paraná R, Santana NP, Lyra L. [Antibodies to hepatitis C virus in patients undergoing hemodialysis in Salvador, BA, Brazil] Arq Gastroenterol 2001; 38: 24-31 PubMed DOI 67 Hruby Z, Sliwiński J, Molin I, Zalewska M, Knysz B, Czyz W, Steciwko A, Bogucki J, Gładysz A. High prevalence of antibodies to hepatitis C virus in three haemodialysis centres in south-western Poland. Nephrol Dial Transplant 1993; 8: 740-743 PubMed 68 Medeiros MT, Lima JM, Lima JW, Campos Hde H, Medeiros MM, Coelho Filho JM. [Prevalence and associated factors to hepatitis C in hemodialysis patients in Brazil] Rev Saude Publica 2004; 38: 187-193 PubMed DOI 69 Amiri ZM, Shakib AJ, Toorchi M. Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran. East Mediterr Health J 2005; 11: 372-376 PubMed 70 Al-Shohaib SS, Abd-Elaal MA, Zawawi TH, Abbas FM, Shaheen FA, Amoah E. The prevalence of hepatitis C virus antibodies among hemodialysis patients in Jeddah area, Saudi Arabia. Saudi Med J 2003; 2: S125 71 Ben Othman S, Bouzgarrou N, Achour A, Bourlet T, Pozzetto B, Trabelsi A. [High prevalence and incidence of hepatitis C virus infections among dialysis patients in the East-Centre of Tunisia] Pathol Biol (Paris) 2004; 52: 323-327 PubMed DOI 72 Shaheen FA, Huraib SO, Al-Rashed R, AlDrees A, Arif M, Al-Jeffry M, Tashkandy MA, Safwat M. Prevalence of hepatitis C antibodies among hemodialysis patients in Jeddah area, Saudi Arabia. Saudi Med J 2003, 2: S125–S126 73 Othman SB, Trabelsi A, Monnet A, Bouzgarrou N, Grattard F, Beyou A, Bourlet T, Pozzetto B. Evaluation of a prototype HCV NS5b assay for typing strains of hepatitis C virus isolated from Tunisian haemodialysis patients. J Virol Methods 2004; 119: 177-181 PubMed DOI 74 López-Alcorocho JM, Barril G, Ortiz-Movilla N, Traver JA, Bartolomé J, Sanz P, Selgas R, Carreño V. Prevalence of hepatitis B, hepatitis C, GB virus C/hepatitis G and TT viruses in predialysis and hemodialysis patients. J Med Virol 2001; 63: 103-107 PubMed DOI 75 Hardy NM, Sandroni S, Danielson S, Wilson WJ. Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol 1992; 38: 44-48 PubMed 76 Hepatitis C virus antibodies in haemodialysis patients. Lancet 1990; 335: 1409-1410 PubMed DOI 77 Ahmetagić S, Hantalasević L, Tihić N, Jusufović E, Stojić V. [Hepatitis C virus infection in hemodialysis patients in General Hospital Gracanica] Med Arh 2006; 60: 298-300 PubMed 78 Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J Viral Hepat 2002; 9: 390-392 PubMed DOI 79 Bdour S. Hepatitis C virus infection in Jordanian haemodialysis units: serological diagnosis and genotyping. J Med Microbiol 2002; 51: 700-704 PubMed 80 Hussein MM, Mooij JM, Hegazy MS, Bamaga MS. The impact of polymerase chain reaction assays for the detection of hepatitis C virus infection in a hemodialysis unit. Saudi J Kidney Dis Transpl 2007; 18: 107-113 PubMed 81 Sullivan DG, Kim SS, Wilson JJ, Stehman-Breen C, Gretch DR. Investigating hepatitis C virus heterogeneity in a high prevalence setting using heteroduplex tracking analysis. J Virol Methods 2001; 96: 5-16 PubMed DOI 82 Iwasaki Y, Esumi M, Hosokawa N, Yanai M, Kawano K. Occasional infection of hepatitis C virus occurring in haemodialysis units identified by serial monitoring of the virus infection. J Hosp Infect 2000; 45: 54-61 PubMed DOI 83 Kondili LA, Genovese D, Argentini C, Chionne P, Toscani P, Fabro R, Cocconi R, Rapicetta M. Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. Eur J Clin Microbiol Infect Dis 2006; 25: 527-531 PubMed DOI 84 Delarocque-Astagneau E, Baffoy N, Thiers V, Simon N, de Valk H, Laperche S, Couroucé AM, Astagneau P, Buisson C, Desenclos JC. Outbreak of hepatitis C virus infection in a hemodialysis unit: potential transmission by the hemodialysis machine? Infect Control Hosp Epidemiol 2002; 23: 328-334 PubMed DOI 85 Savey A, Simon F, Izopet J, Lepoutre A, Fabry J, Desenclos JC. A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol 2005; 26: 752-760 PubMed DOI 86 Alfurayh O, Sabeel A, Al Ahdal MN, Almeshari K, Kessie G, Hamid M, Dela Cruz DM. Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients. Am J Nephrol 2000; 20: 103-106 PubMed DOI 87 Harmankaya O, Cetin B, Obek A, Seber E. Low prevalence of hepatitis C virus infection in hemodialysis units: effect of isolation? Ren Fail 2002; 24: 639-644 PubMed DOI 88 Taskapan H, Oymak O, Dogukan A, Utas C. Patient to patient transmission of hepatitis C virus in hemodialysis units. Clin Nephrol 2001; 55: 477-481 PubMed 89 Gilli P, Soffritti S, De Paoli Vitali E, Bedani PL. Prevention of hepatitis C virus in dialysis units. Nephron 1995; 70: 301-306 PubMed 90 Abacioglu YH, Bacaksiz F, Bahar IH, Simmonds P. Molecular evidence of nosocomial transmission of hepatitis C virus in a haemodialysis unit. Eur J Clin Microbiol Infect Dis 2000; 19: 182-186 PubMed DOI 91 Irish DN, Blake C, Christophers J, Craske JE, Burnapp L, Abbs IC, MacMahon EM, Muir P, Banatvala JE, Simmonds P. Identification of hepatitis C virus seroconversion resulting from nosocomial transmission on a haemodialysis unit: implications for infection control and laboratory screening. J Med Virol 1999; 59: 135-140 PubMed DOI 92 Kokubo S, Horii T, Yonekawa O, Ozawa N, Mukaide M. A phylogenetic-tree analysis elucidating nosocomial transmission of hepatitis C virus in a haemodialysis unit. J Viral Hepat 2002; 9: 450-454 PubMed DOI 93 Olmer M, Bouchouareb D, Zandotti C, de Micco P, de Lamballerie X. Transmission of the hepatitis C virus in an hemodialysis unit: evidence for nosocomial infection. Clin Nephrol 1997; 47: 263-270 PubMed 94 Sánchez-Tapias JM. Nosocomial transmission of hepatitis C virus. J Hepatol 1999; 31 Suppl 1: 107-12 PubMed DOI 95 Rahnavardi M, Hosseini Moghaddam SM, Alavian SM. Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol 2008; 28: 628-640 PubMed DOI 96 Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50: 1-43 PubMed 97 Flett A, Teo M, Mah YI, Mortlock F, Choo BB, Challinor SP, Woods HF. Low seroconversion for hepatitis C virus (HCV) antibody achieved by universal precautions alone. EDTNA ERCA J 1998; 24: 40-42 PubMed 98 Jadoul M. Transmission routes of HCV infection in dialysis. Nephrol Dial Transplant 1996; 11 Suppl 4: 36-38 PubMed 99 Natov SN, Pereira BJ. Hepatitis C in dialysis patients. Adv Ren Replace Ther 1996; 3: 275-283 PubMed 100 Arenas Jiménez MD, Sánchez Paya J, González C, Rivera F, Enríquez R. Isolation of HCV patient is efficient in reducing the annual incidence of HCV infection, but is it really necessary? Nephrol Dial Transplant 1999; 14: 1337-1339 PubMed DOI 101 Djordjević V, Stojanović K, Stojanović M, Stefanović V. Prevention of nosocomial transmission of hepatitis C infection in a hemodialysis unit. A prospective study. Int J Artif Organs 2000; 23: 181-188 PubMed 102 Saab S. Hepatitis C virus transmission in the hemodialysis community. Am J Kidney Dis 2001; 37: 1052-1055 PubMed DOI 103 Saab S, Brezina M, Gitnick G, Martin P, Yee HF Jr. Hepatitis C screening strategies in hemodialysis patients. Am J Kidney Dis 2001; 38: 91-97 PubMed DOI 104 Pol S, Romeo R, Zins B, Driss F, Lebkiri B, Carnot F, Berthelot P, Bréchot C. Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications. Kidney Int 1993; 44: 1097-1100 PubMed DOI 105 Alavian SM. Hepatitis C, Chronic Renal Failure, Control Is Possible! Hep Mon 2006; 6: 51-52
S- Editor Li DL L- Editor Webster JR E- Editor Zheng XM
| |||
|
|
